Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00558038 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy of AST-120 Compared to Lactulose in Patients With Hepatic Encephalopathy
A Phase 2 study, sponsored by Ocera Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 40
- Enrollment target
NCT00558038 is a Phase 2 study that has completed, run by Ocera Therapeutics. The registered enrollment target is 40 participants.
The verdict
NCT00558038, a Phase 2 study, has completed, sponsored by Ocera Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 40 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety and effectiveness of the experimental drug AST-120 compared to lactulose in patients with mild hepatic encephalopathy.
Interventions
- DRUG AST-120
- DRUG lactulose
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2007-09 |
| Est. Completion | 2009-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00558038
The ClinicalTrials.gov registry entry for NCT00558038 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ocera Therapeutics, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which AST-120 is the first listed.
NCT00558038 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00558038 about?
NCT00558038 is a clinical study titled "Safety and Efficacy of AST-120 Compared to Lactulose in Patients With Hepatic Encephalopathy". The purpose of this study is to evaluate the safety and effectiveness of the experimental drug AST-120 compared to lactulose in patients with mild hepatic encephalopathy.
What is the current status of trial NCT00558038?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2007-09. Estimated completion is 2009-06.
What interventions are being tested in trial NCT00558038?
The interventions under investigation include: AST-120 (DRUG), lactulose (DRUG).
Who is sponsoring clinical trial NCT00558038?
This trial is sponsored by Ocera Therapeutics, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.